报价延迟最少15分钟:2026/04/15 09:41 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.39 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.52/-1.31
|
|
企业价值
243.01M
|
| 资产负债 |
|
每股账面净值
1.07
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focusedon the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS. |
